Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma Academic Article uri icon

Overview

MeSH Major

  • Antibiotics, Antineoplastic
  • Doxorubicin
  • Granulocyte Colony-Stimulating Factor
  • Sarcoma

abstract

  • LED can be administered every 2 weeks at a dose of 105 mg/m2 with G-CSF support, which provides a dose-intensity of 52.5 mg/m2/wk. To exceed this intensity, the dose of LED that would have to be administered every 3 weeks would be greater than 157.5 mg/m2. A formal phase II trial is needed to estimate better the true response rate.

publication date

  • May 1997

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 9164225

Additional Document Info

start page

  • 2111

end page

  • 7

volume

  • 15

number

  • 5